Table 1

 Summary of the results of demographics, disease and drug details of patients with and without neutropenia receiving anti-tumour necrosis factor treatment

Neutropenia (<2.0×109/l) (%)No neutropenia (%)Statistics
ANA, antinuclear antibodies; DMARDs, disease-modifying antirheumatic drugs; TNF, tumour necrosis factor.
n (%)19 (14.3)114 (85.7)
Female16 (15.4)88 (84.6)χ2 = 0.47, p = 0.5
Male3 (10.3)26 (89.7)
Mean age (years)57.456.6t = 0.25, p = 0.8
Anti-TNF drugs
    Adalimumab3 (14.3)18 (85.7)χ2 = 0.08
    Etanercept13(15.3)62 (84.7)p = 0.96
    Infliximab3 (13.1)20 (86.9)
Baseline neutrophil count3.776.12t = 4.85, p<0.001
Baseline total white cell count5.888.82t = 5.23, p<0.001
Neutrophils:white cell count ratio0.620.68t = 2.73, p = 0.007
ANA positive7/65 (10.8)58/65 (89.2)χ2 = 0.001, p = 0.97
ANA negative4/38 (10.5)34/38 (89.5)
On methotrexate5/47 (10.6)42/47 (89.4)χ2 = 0.79, p = 0.37
Not on methotrexate14/86 (16.3)72/86 (83.7)
On prednisolone4/53 (7.5)49/53 (92.5)χ2 = 3.2, p = 0.07
Not on prednisolone15/80 (18.8)65/80 (81.2)
Neutropenia on previous DMARDs
    Yes11/23(47.8)12/23 (53.2)χ2 = 25.5, p<0.001
    No8/110 (7.3)102/110 (82.7)